Takeda Pharmaceuticals U.S.A., Inc.

Lupin Gains FDA Approval for Generic Adderall XR for ADHD Treatment

• Lupin has received FDA approval for its generic version of Adderall XR, an extended-release capsule used to treat ADHD in adults and children. • The approved Abbreviated New Drug Application (ANDA) includes multiple dosage strengths, ranging from 5 mg to 30 mg. • Lupin's generic equivalent of Adderall XR is poised to enter a market with annual sales of $865 million, based on IQVIA MAT September 2024 data. • The drug will be manufactured in Lupin’s Somerset facility in the United States, ensuring a domestic supply of this critical medication.